Published in Cancer Weekly, February 18th, 2003
The authors "determined a novel criteria defined by BCD5(+)CD79b(-/low)/total BCD5(+) cells ratio (BCD5(+)R), and compared it with the previous definition of phenotypic remission, based on CD19(+)CD5(+) coexpression with complementarity-determining region 3 polymerase chain reaction (CDR3 PCR) and clonotypic PCR (cPCR). A series of 54 peripheral blood samples from 21 chronic lymphocytic leukemia (CLL) patients in complete hematological remission and 16 samples from normal volunteers were analyzed."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.